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Initial antibody responses to transmitted/founder 
HIV-1 envelope (Env) do not arise until 13 d 
after the onset of viremia, target gp41, and are 
nonneutralizing (Tomaras et al., 2008). Whereas 
early T cell responses to HIV-1 that are coinci-
dent with these initial antibody responses drive 
viral evolution for escape mutants, the early gp41 
Env antibody response does not (Bar et al., 2009; 
Goonetilleke  et  al.,  2009;  McMichael  et  al., 
2010). Instead, the first antibodies capable of   
selecting viral mutants are gp120 autologous 
neutralizing antibodies that appear only months 
after transmission (Richman et al., 2003; Wei   
et al., 2003; Moore et al., 2009).
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The initial antibody response to HIV-1 is targeted to envelope (Env) gp41, and is non-
neutralizing and ineffective in controlling viremia. To understand the origins and characteris-
tics of gp41-binding antibodies produced shortly after HIV-1 transmission, we isolated and 
studied gp41-reactive plasma cells from subjects acutely infected with HIV-1. The frequen-
cies of somatic mutations were relatively high in these gp41-reactive antibodies. Reverted 
unmutated ancestors of gp41-reactive antibodies derived from subjects acutely infected 
with HIV-1 frequently did not react with autologous HIV-1 Env; however, these antibodies 
were polyreactive and frequently bound to host or bacterial antigens. In one large clonal 
lineage of gp41-reactive antibodies, reactivity to HIV-1 Env was acquired only after 
somatic mutations. Polyreactive gp41-binding antibodies were also isolated from uninfected 
individuals. These data suggest that the majority of gp41-binding antibodies produced 
after acute HIV-1 infection are cross-reactive responses generated by stimulating memory 
B cells that have previously been activated by non–HIV-1 antigens.
© 2011 Liao et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS
The plasma cell response in AHI
The frequency (mean percentage) of plasma cells in AHI 
subjects was 6.5 ± 2.8% of total B cells (Fig. 1 A). We pro-
duced 977 recombinant mAbs from plasma cells of five 
AHI subjects (Table I and Fig. 1 B). To ensure that no 
HIV-1  Env  antibodies  were  missed,  autologous  HIV-1 
gp140 proteins derived from the single transmitted/founder 
virus from subjects 684–6 and 681–7, as well as a group M 
consensus Env gp140 and a clade B recombinant (r) gp41, 
were used to screen antibodies in binding assays (Tomaras   
et al., 2008).
Of 977 mAbs from AHI subjects, 67 (6.9%) were HIV-1 
Env reactive, and of those 67 mAbs, 61 (6.2%) were reactive 
with gp41, 2 (0.2%) were reactive with gp120, and 4 (0.4%) 
were reactive with only aldrithol-2 (AT-2)–inactivated HIV-1 
clade B virions (Fig. 1 B and Table S1). Plasma cell–derived 
IgA1, IgG1, and IgG3 isotype usage predominated for HIV-1– 
reactive and non-HIV-1–reactive antibodies (Table S1). 
VH gene family usage in AHI HIV-reactive antibodies were 
19.0% VH1, 54.0% VH3, and 12.7% VH4, respectively, and 
were similar to the distribution of VH families in 34,384 VH 
sequences collected in the National Center for Biotechnol-
ogy Information database (Table S2).
The average complementarity-determining region (CDR) 
H3 length of AHI antibodies in amino acid residues was 15.1 ± 
0.4 (Table S3), and mutation frequency in  VH gene segments was 
5.0 ± 0.4% (Fig. 1 C and Table S4). There were no significant 
The progeny of B cells that respond initially to microbial 
pathogens or vaccines may be sampled in the transient plasma-
cytosis that appears in the circulation 7 d after immuniza-
tion (Falkoff et al., 1983; Wrammert et al., 2008). To define 
the clonal nature of early humoral responses to HIV-1 Env, 
we isolated single CD19+, CD27hi, CD38hi, and CD20lo or 
CD20 plasmablasts and/or plasma cells (hereafter termed 
plasma cells) from the blood or bone marrow of acute HIV-1 
infection (AHI) subjects and used RT-PCR to amplify re-
arranged variable regions of Ig heavy and light chain genes (VH 
and VL, respectively; Wardemann et al., 2003; Tiller et al., 2008; 
Wrammert et al., 2008; Liao et al., 2009) for Ig gene analysis 
and for production of recombinant mAbs. AHI subjects were 
studied at 17–30 d after HIV-1 transmission, during a pe-
riod of plasmacytosis. The levels of antibody mutation fre-
quencies during this period of plasmacytosis were compared 
with those induced by primary HIV Env immunization in 
uninfected subjects. Our analysis demonstrated that HIV-1–
reactive antibodies in the initial response to HIV-1 in the set-
ting of AHI were more somatically hypermutated than Env 
antibodies  isolated  after  primary  HIV-1  Env  vaccination. 
Analysis of VH sequences of genomic DNA by 454 deep se-
quencing of four HIV-1 Env-reactive clonal lineages from 
AHI subjects did not reveal any unmutated lineage members. 
Similarly rare gp41-reactive mutated mAbs could be isolated 
from uninfected subjects. These data suggested that many ini-
tial Env antibodies in AHI may arise from preexisting mu-
tated Env-cross reactive memory B cells.
Figure 1.  Plasma cell response in AHI. (A) Sorting of plasma cells from AHI subjects (681–7, 684–6, 001–4, 0689 and 065–0). Dot plots were gated on 
CD3CD14CD16CD235aCD19+ B cells (cells were also gated as CD20lo/ during sorting). Ovals designate the populations that were sorted as plasma 
cells (CD27hi/+ and CD38hi/+). Numbers indicate percentage of cells in the sort gate. LKP, leukapheresis cells. (B) Specificity of antibodies isolated from 
plasma cells from each subject, or from all five AHI subjects pooled together. Total numbers of antibodies were indicated at the center of each pie chart. 
Percentage of antibodies binding to gp41, gp120, AT-2 inactivated HIV-1 clade B virion, and non–HIV-1/nondefined antigens are indicated in different 
colors. (C and D) Frequency of somatic mutations in VH gene segments of antibodies isolated from all five AHI subjects or from individuals 14 d after the 
second immunization (42 d after first dose) or 14 d after the fourth immunization (182 d after first dose) with gp120/NefTat/AS01B (D).JEM Vol. 208, No. 11 
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reactive with HIV-1 gp41 Env (Table S6). Antibodies within 
five HIV-1 gp41-reactive clonal lineages were expressed and 
studied in this work (Fig. 2, Table II, and Tables S7–S11).   
One surprisingly large clonal family (clonal lineage 558 from 
subject 684–6 20 d after transmission) contained 51 mem-
bers (17 unique; Fig. 2 A and Table S7).
We considered two possible origins for the gp41-reactive, 
highly mutated B cells recovered from AHI subjects. First, 
HIV-1 gp41 Env may trigger a naive B cell to proliferate and 
mutate to this degree, despite reductions of CD4+ T cell 
numbers  and  disruption  of  mucosal  germinal  centers  that   
occur in AHI (Brenchley, et al., 2004; Levesque et al., 2009). 
Although it is possible, we thought that this scenario was less 
plausible because of the low number of mutations that de-
velop in the time from HIV-1 transmission to the time when 
blood is collected for plasma cell sorting (17–30 d; Keele et al., 
2008). Second, HIV-1 gp41 may trigger preexisting mutated 
B cells that cross react with gp41, and after stimulation by 
gp41Env, Env may become the trigger for further antibody 
affinity maturation.
To directly test the hypothesis that autologous Env reac-
tivity in AHI clonal lineages can arise distal to a founder naive 
B cell, we used somatic diversification analysis-2 (SoDA-2; 
Volpe et al., 2006; Munshaw and Kepler, 2010) and DNA 
maximum likelihood (Felsenstein, 1973, 1981, 2005) pro-
grams to infer reverted unmutated ancestors (RUAs) of clonal 
lineages 558, 572, 712, and 728 (Fig. 2, A–D; and Tables S7–11) 
from subject 684–6 and clonal lineage 2495 from subject 
001–4 (Fig. 2 E and Table S11), and also to infer reverted in-
termediate antibodies in clonal lineage 558 (Fig. 2 A and 
Table S7). Inferred RUAs and intermediates and observed 
antibodies from subject 684–6 were assayed against recombi-
nant (r) Env gp140 derived from the autologous transmitted/
founder virus (Keele et al., 2008).
As naive B cells responding to antigens often have low   
affinity binding in vivo (Dal Porto et al., 2002; Shih et al., 
2002), we used Luminex assays and surface plasmon reso-
nance (SPR) to assess the Env reactivity of RUAs of HIV-1 
differences  in  mutation  frequencies  among  Env  gp41–,  Env 
gp120–, or AT-2–inactivated virion-reactive antibodies (Fig. S1). 
The frequency of VH mutations in acute HIV-1 antibodies was 
high when compared with antibodies from the reported pri-
mary response to rotavirus infection (0.3%; Weitkamp et al., 
2003), and were more similar to mutation frequencies of anti-
bodies from the previously reported secondary responses to in-
fluenza vaccination (6.5%; Wrammert et al., 2008).
Mutation frequency in antibodies from a primary  
HIV-1 Env immunization
To determine the mutation frequency of a true primary response 
to HIV-1 Env in the setting of vaccination, we isolated 14 anti-
gp120 Env antibodies 14 d after the second immunization (total 
of 42 d after the first priming immunization) with recombinant 
HIV-1 W61D gp120 and 20 anti-gp120 Env antibodies 14 d after 
the fourth immunization (total of 182 d after the first prime) with 
the same immunogen (Leroux-Roels et al., 2010). We found that 
4 of 14 HIV-1–reactive Env antibodies (29%) isolated 14 d after 
2 immunizations (42 d after initial immunization) had unmutated 
VH sequences, and the mean VH mutation frequency of these   
14 antibodies was 1.5% (±0.5%; n = 14; Fig. 1 D and Table S5). 
In contrast, the mean VH mutation frequency of 20 antibodies 
isolated 182 d after 4 Env immunizations was 4.8% (±0.5%;   
Fig. 1 D and Table S5). The total number of unmutated HIV-1–
reactive antibodies found in AHI was 7 of 67 (10.4%; all gp41 re-
active; Fig. 1 C and Fig. S1), and was lower than that found in the 
unmutated antibodies (28.6%) isolated after primary HIV-1 Env 
vaccination (P = 0.09; Fisher’s exact test). Furthermore, the mean 
VH mutation frequency of the plasma cell antibodies 17–30 d   
after transmission in AHI (5.0 ± 0.4%) was significantly higher 
than that of antibodies from the day 42 primary response to Env 
immunization (1.5 ± 0.5%; P < 0.0001, Student’s t test)
Clonality of the Env antibody response  
in HIV-1 acute infection
Within 977 AHI plasma cell–derived antibodies, we identi-
fied 35 clonal lineages, of which 12 contained members 
Table I.  Clinical information of 5 AHI patients
Subjectsa Age (gender) Days since 
infectionb
Viral load 
copies/ml
CD4 count 
cells /µl
 Plasma anti–HIV-1 gp41 Fiebig 
stagec
EIA Western blot IgM IgG IgA
065-0 35 (M) 17 391 269 Neg. Neg. Neg. Neg. Neg. 2/1
068-9d 37 (M) 30 258 611 Pos. Neg. Pos. Neg. Neg. 3
681-7 42 (M) 20 5,900,000 230 Neg. Neg. Neg. Neg. Neg. 2/1
684-6 32 (M) 20 10,925,000 225 Pos. Neg. Pos. Pos. Pos. 3
001-4 26 (M) 20 4,700,000 165 Pos. Ind. Pos. Pos. Pos. 4
EIA, enzyme immunoassay; Neg., negative; Pos., positive; Ind., indeterminate, as one or more bands are present but the blot did not meet the criteria for positive in that at 
least one of gp160 and/or gp120, gp41, or gp24 must be present.
aPatient no. 068-9 received ART for 7 d after exposure, 21 d before blood and bone marrow samples were obtained from.
bDays since infection were determined by clinical information of last contact or by days from onset of AHI symptoms. All patients had admitted to hospitals of recent contact 
except 684-6, who had AHI symptoms and had negative Western blot analysis with high plasma viral load.
cBased on description reported by Fiebig et al (2003).
dAll five subjects were quickly placed on antiretroviral therapy soon after diagnosis and consequently none developed detectable autologous or heterologous neutralizing 
antibodies during up to 2 yr of follow up (unpublished data).2240 Early HIV-1 gp41-binding antibodies | Liao et al.
An additional gp41 clonal lineage from 
subject 001–4 (clone 2495; Fig. 2 E and   
Table S11) was also studied, and the 2495 
RUA, like the RUA of clonal lineage 
558, was rgp41 nonreactive, whereas the 
lineage 2495 observed antibody (H2136-
L773) was strongly rgp41 reactive in SPR 
assay (dissociation constants [Kd] = 4.3 nM; Fig. 3 B), as well 
as in Luminex assays (Fig. S2 A).
Next, observed antibodies, the RUA, and intermediate 
antibodies of clonal lineage 558 (Fig. 2 A and Table S7) were 
assayed against HIV-1 clade B rgp41, autologous rgp140, and 
group M consensus (CON-S) rgp140 in Luminex assays   
(Tomaras et al., 2008) to determine where the HIV-1 Env   
reactivity of antibodies in clone 558 was acquired (Fig. 4).   
Although neither clone 558 RUA nor the earliest intermedi-
ate antibody (no. 1) reacted with rgp41, autologous rgp140, or 
CON-S rgp140, the reverted intermediates 6 and 9 and ob-
served antibody H828-K616 all bound well to the three Env 
proteins (Fig. 4 A). Thus, in clone 558, autologous Env and 
rgp41 did not react with the inferred RUA or with interme-
diate no. 1, suggesting that Env reactivity was indeed acquired 
after somatic mutations had been induced in the RUA and 
inferred intermediate no. 1 by an as yet unknown antigen.
Env-reactive clonal lineages from AHI, RUAs, and observed 
antibodies. We found that none of the four RUAs from sub-
ject 684–6 reacted with autologous rgp140 in SPR assays 
(Fig. 3 A), whereas observed antibodies from each clone did 
react with autologous rgp140 in SPR assays (Fig. 3 A). Thus, 
detectable reactivity of all 4 clones from subject 684–6 with 
autologous transmitted/founder rgp140 appeared to be ac-
quired after somatic hypermutation of the RUA. Interest-
ingly, 3 of 4 subject 684–6 RUAs from lineages 572, 712, 
and 728 did cross react with heterologous clade B rgp41 in 
both SPR (Fig. 3 B) and Luminex assays (Fig. S2 A). This 
finding  suggested  either  that  cross-reactivity  of  the  RUA 
with  rgp41  reflected  epitope  similarity  of  rgp41  with  the 
non–HIV-1 antigen that triggered the gp41 antibodies, or 
suggested that autologous recombinant 684–6 rgp140 protein 
does not express the gp41 epitopes that were expressed on 
native 684–6 transmitted/founder Env in virions in vivo.   
Figure 2.  Phylogenetic trees of antibody 
clonal lineages derived from AHI. Clonal lin-
eages 558 (A), 572 (B), 712 (C), 728 (D), and 2495 (E) 
were obtained from AHI subject 684–8. Clonal 
lineage 2495 was obtained from AHI subject 001–4. 
Antibodies highlighted in red for each clonal  
lineage were gp41 reactive and antibodies labeled 
in black font were gp41-negative in the initial 
screening. The length of lines in scale indicates 
extent of nucleotide differences between indi-
vidual antibodies. Numbers underneath the scale 
lines indicate frequency of mutation; 0.01 = 1% 
sites mutated or 0.1 = 10% sites mutated.  
Inferred unmutated ancestors (RUAs) are indi-
cated by red triangles in each clonal lineage. For 
clonal lineage 558 (A), numbers under or beside 
lines denote numbers of nucleotides of VH and VK 
chain genes of individual antibodies that differ 
from each other, and numbers in parentheses 
indicate the number of antibodies that had iden-
tical sequences. Inferred reverted intermediate 
antibodies are indicated by red square boxes for 
clonal lineage 558.
Table II.  Plasma cell clonal lineages studied from AHI
Clone ID Reactivity Subject Ig class, isotype 
(number)
VH DH JH VK or VL JK or JL No. of members
558 HIV-1 gp41 684-6 IgG3(50), G1(1) 3–7 1–26 5 1–39 4 51
572 HIV-1 gp41 684-6 G1(2), G3(1) 3–48 2–2 6 3–20 4 3
712 HIV-1 gp41 684-6 A1 3–23 3–10 5 1–39 4 5
728 HIV-1 gp41 684-6 G1(2), A1(1) 1–3 2–15 6 1–39 4 3
2495 HIV-1 gp41 001-4 G3 1–2 2–21 3 3–21 2 3JEM Vol. 208, No. 11 
Article
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Figure 3.  Binding of RUA antibodies and observed antibodies to 684–6 transmitted/founder gp140 and to HIV-1 MN rgp41 was analyzed 
by SPR. RUAs and observed antibodies were derived from HIV-1 gp41-reactive clonal lineages 558, 572, 712, and 728 as indicated at the top of each 
graph. Approximately 1,000–3,000 Response Units of 684–6 gp140 (A) or HIV-1 MN rgp41 (B) were immobilized on adjacent flow cells of the same sensor 
chip. Each antibody was injected in a dose range starting at 100 µg/ml for 3 min at 30 µl/min on a BIAcore 3000 instrument (GE Healthcare) using PBS, 
pH 7.4, as running buffer. For binding Kd measurements, each antibody that bound to 684–6 gp140 (A) or to HIV-1 MN rgp41 (B) was injected at concen-
trations ranging from 80 to 1µg/ml and at a flow rate of 50 µl/min for 3min. Data are representative of three separate experiments.2242 Early HIV-1 gp41-binding antibodies | Liao et al.
It was important to determine evidence of antigen drive 
in clonal lineage 558. Selection for replacement mutations 
was reflected in synonymous and nonsynonymous muta-
tions in clone 558 VH and VL CDR and framework regions   
(Table  S12). Whereas 85.7% of Ig CDR mutations were 
nonsynonymous, only 68.8% of framework mutations were 
nonsynonymous (2 = 15.3; P < 106).
We also asked if the affinity of antibody binding to rgp41 
increased as somatic mutations accumulated. We produced 
additional reverted inferred intermediate antibodies of lineage 
558 (Fig. 2 A), evaluated the binding of these antibodies to 
HIV-1 Env rgp41 using Luminex assays (Tomaras et al., 2008), 
and determined their Kd of binding to HIV-1 Env rgp41. 
With the accumulation of mutations, the individual apparent 
affinities (Kd) of clone members for gp41 binding in general 
increased, e.g., from 63.3 nM at inferred intermediate no. 6 
to 4.7 nM at antibody H789-K584, and to 0.6 nM at ob-
served antibody H828-K616 (Table III).
We next asked if deep sequencing could reveal examples of 
unmutated or less extensively hypermutated VH sequences of 
antibodies in gp41 clonal lineages. Thus, we performed 454 
deep sequencing on V(D)J gene segments (Boyd et al., 2009) of 
genomic DNAs derived from PBMCs of all 5 acute HIV-1 sub-
jects and obtained an average depth of total of 3,300 Ig VH se-
quences per subject. We found the VH sequences of four HIV-1 
gp41 clonal lineages (Fig. 4 B) that had been initially identified 
among antibodies derived from the sorted single plasma cells 
(Table S6). These included 63 VH sequences with mutation 
frequencies ranging from 3.5 to 13.5% for clone 572, 75 VH 
sequences with mutation frequencies from 1.5 to 10.8% (me-
dian, 11.1%) for clone 748, 12 VH sequences with mutation 
frequencies from 8.2 to 11.4% (median, 11.1%) for clone 
2495, and, finally, 507 VH sequences with mutation frequen-
cies ranging from 2.5 to 11.6% (median, 5.6%) for clonal 
lineage 558 (Fig. 4 B and Table S6). Importantly, we found 
no unmutated VH sequences, or even any sequences with fewer 
than three mutations, in any of these four clonal lineages, a 
finding compatible with the hypothesis that many of the re-
sponding antibodies to gp41 stimulation are derived from 
preexisting memory B cells.
Polyreactive nature of the initial antibody response to Env
We determined polyreactivity of AHI gp41 antibodies with 
gut flora whole-cell lysate antigens by Luminex assays (Tomaras 
et al., 2008). Reactivity of the RUAs and/or observed antibodies 
in clonal lineages 558, 572, and 728 with gut flora was present 
Figure 4.  Characteristics of anti–HIV-1 gp41 Env clonal lineages. 
(A) Analysis of the reactivity of inferred RUA, intermediates, and observed 
antibodies in clonal lineage 558 with HIV-1 rgp41, autologous Env gp140, 
and CON-S Env gp140. The RUA (triangle) and reverted intermediates 1, 6, 
and 9 (square boxes), as well as observed antibody H828-K616, were  
assayed for reactivity with rgp41, autologous 684–6 gp140, and the group 
M consensus gp140 CON-S by Luminex assays. (B) VH sequences of clonal 
lineages identified by 454 deep sequencing. Shown are the numbers of 
clonal sequences (on the y axis) with the percentage of nucleotide change 
from germline sequences (on the x axis) for each of HIV-1 Env-reactive 
clonal lineage m (indicated by clonal lineage number with number of 
sequences found in parentheses) identified by 454 deep sequencing from 
genomic DNA of B cells of acute HIV-1 subjects. Sequences with identical 
V, D, and J segment usage and identical V-D and D-J junctions were con-
sidered to be members of an individual B cell clone. Data are representa-
tive of three separate experiments.
Table III.  Apparent binding affinity of observed, RUA, and 
intermediate antibodies in clonal lineage 558 to HIV-1 gp41
Antibody ID EC50 Apparent Kd
µg/ml nM
H789-K584 0.7 4.7
H684-K462 56.3 375.3
H828-K616 90 0.6
CL558_RUA NB NA
CL558_1 NB NA
CL558_2 26.7 0.2
CL558_5 22.8 152
CL558_6 9.5 65.3
CL558_7 7.8 52
CL558_9 25.7 171.3
CL558_13 18.2 121.3
CL558_14 21.9 146
CL558_15 5.3 35.3
CL558_16 2.1 14
Binding of antibodies to HIV-1 gp41 was determined in Luminex assays at  
antibody concentrations ranging from 50 to 0.2 µg/ml. NB, No detectable  
binding; NA, not applicable.JEM Vol. 208, No. 11 
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Env antibodies neutralized the autologous transmitted/founder 
viruses of subject 684–6 in pseudovirus neutralization assays 
(not depicted).
One explanation for the polyreactivity seen in HIV-1 
gp41 RUAs and their progeny is that HIV-1 may be activat-
ing a polyreactive pool of B cells. Tsuiji et al. (2006) have 
demonstrated  that  a  subset  of  the  human  IgM+,  CD27+ 
memory (mutated) B cell compartment is reactive with bac-
terial antigens. We found that 8 of 11 (72.7%) of the observed 
gp41 antibodies in the clonal lineages tested reacted with anti-
gens present in lysates of gut flora (Fig. S2 A). Thus, we hypoth-
esized that, if a subset of the IgM memory pool of B cells 
were being preferentially activated in AHI, then rgp41+ mu-
tated IgM B cells should also be present in acute infection.
In this regard, 4 of 61 rgp41 mAbs isolated from blood 
plasma cells were IgMs. Although 1 IgM was unmutated, the VH 
mutations in 3 IgM gp41 mAbs were 4.0, 4.8, and 5.9%. In ad-
dition, using Epstein-Barr virus (EBV) transformation (Levesque 
et al., 2009), we isolated a mutated human VH4-4 IgM mAb 
1E7 (VH mutation frequency, 1.9%) from bone marrow of a 
subject with recent HIV-1 infection that reacted with HIV-1 
gp41 Env and cross reacted with gut flora antigens (Fig. S4), but 
did not neutralize HIV-1 (unpublished data). Thus, polyreactive 
nonneutralizing mutated IgM antibodies are being activated in 
AHI that react with HIV-1 Env rgp41.
Mutated HIV-1 Env-reactive antibodies are present  
in HIV-1 uninfected subjects
If the notion is plausible that the initial HIV-1 Env responses 
can be generated, at least in part, by HIV-1 Env gp41 interact-
ing with memory B cells that express a B cell receptor that has   
been mutated as a result of stimulation by a non–HIV-1 anti-
gen, then such antibodies should exist in HIV-1–uninfected   
subjects. We have identified 3 IgG1 antibodies (Ab1144, 
Ab929, and Ab931) from a total of 270 antibodies generated 
from plasma cells sorted from PBMC of 2 uninfected subjects 
using the same plasma cell sorting strategy 
for isolation of AHI, and one IgM antibody 
generated by EBV transformation of B cells 
from  an  uninfected  terminal  ileum  (C14; 
Table IV and Fig. 6 A).  All these antibod-
ies reacted with 4 HIV-1 Env rgp41 and 
were  mutated  with  a  mean  VH  mutation 
frequency of 7.0 ± 3.0%. Two of three IgG 
but weak (Fig. S2 A), whereas the RUAs of clonal lineage 
2495 did not react with gut flora antigens (Fig. S2 A). In con-
trast, the three observed gp41 antibodies of lineage 712 reacted 
strongly with gut flora (Fig. S2 A), while the RUA of clonal 
lineage 712 did not react with gut flora antigens (Fig. S2 A).
We  also  tested  RUAs  and  observed  antibodies  from 
clones 558, 572, 712, 728, and 2495 for polyreactivity by   
assaying for reactivity with HEp-2 epithelial cells. Although 
neither the clonal lineage 558 RUA nor inferred intermedi-
ate 1 reacted with HEp-2 cells, inferred intermediate 6 did—a 
change in specificity that coincided with the acquisition of 
reactivity for rgp41. In contrast to the increase in affinity for 
rgp41 in the 558 lineage, reactivity to HEp-2 cells in the 
clonal lineage waxed and waned (Fig. 5).
In the other lineages, several patterns of HEp-2 reactivity 
were seen (Fig. S2 B). In lineage 572, the RUA and observed 
mAb H656-K469 were HEp-2 reactive, whereas observed mAb 
H792-K586 was nonreactive. Similarly, the RUA and ob-
served antibodies H705-K506, H708-K509, and H758-K563 
in clonal lineage 712 were HEp-2 reactive. The RUA of clonal 
lineage 728 was also HEp-2 positive, but observed mAb H820-
K607 was negative. Finally, the RUA of clonal lineage 2495 
was similar to lineage 558 and was not polyreactive for HEp-2 
cells (Fig. S2 B), whereas observed gp41 antibody H2136-
L773 in lineage 2495 was polyreactive (Fig. S2 B).
The specificity of gp41-reactive antibodies in clone 558 
was to a conformational determinant on rgp41 recognized 
best on blue native gels (Fig. S3 A). Interestingly, although 
weakly reactive with gut flora in Luminex (Fig. S2 A), lineage 
558 gp41 antibody CL558_2 cross reacted with a 520-kD 
molecule present in both aerobic and anaerobic gut flora   
lysates, providing candidates for one source of non–HIV-1 anti-
gens that could prime for cross-reactive antibody responses 
with HIV-1 Env (Fig. S3 B).
Regarding AHI gp41 antibody neutralization of HIV-1, 
as expected (Tomaras et al., 2008), none of the observed   
Figure 5.  Binding of the RUA, inferred re-
verted intermediate antibodies, and observed 
antibodies in clonal lineage 558 to HEp-2 epi-
thelial cells in the indirect immunofluorescence 
staining assays. Numbers in square boxes are in-
ferred intermediate antibodies. The observed anti-
body members are highlighted in red font. Positive 
or negative immunofluorescence staining of anti-
bodies on HEp-2 epithelial cells is indicated above 
the pictures for the indicated antibodies. Data are 
representative of three separate experiments.2244 Early HIV-1 gp41-binding antibodies | Liao et al.
that polyreactive antibodies that cross react with HIV-1 Env 
can be isolated from HIV-1 uninfected subjects.
Although 30% of antibodies isolated 42 d after HIV-1 
Env priming with 2 immunizations were unmutated, only 
10.4% of plasma cell–derived AHI HIV-1 antibodies were 
unmutated. Moreover, in the Env clonal response in AHI, 
VH deep sequencing did not reveal any unmutated members 
of four of the Env clonal lineages in this study. In a primary 
vaccination response to HIV-1 Env, we found the VH muta-
tion frequency to be 1.5% (Fig. 1 D). Even after a secondary 
boosting in an Env vaccine setting, we were able to find 1 of 
20 Env antibodies that were unmutated. Similarly, in a primary 
antibody response to rotavirus infection, Weitkamp et al. found 
and one IgM gp41-reactive antibodies were polyreactive with 
reactivity to multiple autoantigens (Fig. 6 B), although not to 
our gut flora whole-cell lysate (not depicted). In SPR assays, 
three IgG1 antibodies (Ab1144, Ab929, and Ab931) isolated 
from an uninfected subject (022–3) had HIV-1 gp41-binding 
affinity of 4.8 , 17, and 32.4 nM (Fig. 6 C), respectively, which 
are similar in affinity to gp41-positive antibodies isolated from 
acute HIV-1 subjects (Fig. 3 B).
DISCUSSION
In this study, we have demonstrated that the HIV-1 Env 
gp41 plasma cell repertoire of subjects early in AHI is fre-
quently polyreactive with host cell and gut flora antigens and 
Table IV.  HIV-1 Env-reactive antibodies isolated from uninfected subjects
VH VK/L
PTID ID Isotype Family Mutation 
frequency
CDR3 
length 
  ID Family Mutation 
frequency
CDR3 
length 
Specificity
% aa % aa
022-3 H0929 G3 3–23 7.7 18 0308 VL1–47 0.035 11 gp41
022-3 H0931 G3 4–61 10.4 24 0692 VK3–15 8.6 11 gp41
022-3 H1141 G1 3–48 7.5 17 0378 VL3–10 3.6 11 gp41
C14 HC14-2 M 3–74 3.0 8   C14-2 VL1–44 0.7 12 gp41
Figure 6.  Reactivity of antibodies isolated from uninfected subjects. Three IgG antibodies (Ab1144, Ab929, and Ab931) and one IgM antibody 
(C14) in threefold dilutions ranging from 50 to 0.2 µg/ml (x axis) were evaluated for reactivity with HIV-1 rgp41 by Luminex assays (A) and for reactivity 
with a panel of autoantigens by ANA assays (B). The dotted lines indicate the cutoff values ≥120 luminance units used to denote positivity. Binding affin-
ity of Ab1144, Ab929, and Ab931 in dose ranges (starting concentration at 40 µg/ml) to HIV-1 MN gp41 was measure by SPR (C). Data are representative 
of at least two separate experiments.JEM Vol. 208, No. 11 
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influenza vaccination (Wrammert et al., 2008) and in pandemic 
H1N1 swine influenza infection (Wrammert et al., 2010). How-
ever, a similar polyclonal response has been seen in mice in 
 herpes virus infections (Sangster et al., 2000) and in humans 
with seasonal influenza infections (unpublished data). Thus, 
this degree of polyclonal activation is not unique to AHI.
We and others have previously reported Env-reactive   
B cells from HIV-1–uninfected subjects (Berberian et al., 
1993; Chin et al., 1995; Chen et al., 2009; Levesque et al., 
2009). The importance of our studies here is that with the 
same methods as used in AHI subjects, we can isolate rare 
mutated IgG and IgM antibodies with binding properties 
similar to those isolated from AHI (Fig. 6 and Table III), a 
finding that is critical to the hypothesis that HIV-1 Env can 
activate previously activated, mutated memory B cells that 
have Env cross reactivity. Moreover, we have found a range 
of reactivity of uninfected human sera to gp41 Env recombi-
nant proteins (unpublished data). Several studies, including 
studies presented here, have demonstrated with a variety of 
techniques that HIV-1–reactive B cells are present before in-
fection in humans. Our present studies suggest that a subset 
of these B cells is involved in the initial response to HIV-1 
Env gp41 in AHI.
Why  gp120  antibodies  that  neutralize  the  autologous 
transmitted/founder virus only develop 3 mo or longer after 
transmission—too late to prevent or control infection—is not 
clear (Wei et al., 2003; Richman et al., 2003; Keele et al., 
2008). This initial gp41 antibody response in AHI does not 
select HIV-1 escape mutants (unpublished data). That a non-
neutralizing, nonprotective gp41 response occurs first, and 
the potentially protective gp120 response occurs late, sug-
gests some type of immune modulation or direction by gp41 
away from an initial gp120 response. It will be of great inter-
est to probe the plasma cell and memory B cell repertoires of 
HIV-1 subjects as they evolve autologous neutralizing anti-
body responses, and to determine the fates of gp41 clonal lin-
eages as gp120 clonal lineages arise.
In summary, our study provides considerable new insight 
into the dysfunctional nature of the initial antibody response 
to HIV-1 in AHI. That the initial antibodies are polyreactive 
and more mutated than expected provides evidence consis-
tent with the hypothesis that HIV-1 diverts the initial antibody 
response to Env by stimulating mutated B cells that have been 
previously activated by non-HIV-1 antigens, thus rendering the 
earliest antibody responses to HIV-1 nonprotective.
MATERIALS AND METHODS
Study  subjects. Blood and bone marrow samples were collected from   
5 AHI subjects at 17 to 30 d after transmission, as estimated from patient his-
tory and Fiebig classification (Table I) for plasma cell sorting and for isolation 
of genomic DNA for sequence analysis of V(D)J segments of Ig heavy chain 
genes by the 454 platform with Titanium chemistry (Roche). Table I shows 
the characteristics of the subjects studied. Subjects 065–0 and 641–7 were at 
Feibig Stage 1 according to the Fiebig classification (Fiebig et al., 2003), 
whereas subjects 068–9, 684–6, and 001–4 were at Feibig stage 2. Five sub-
jects immunized with gp120/NefTat/AS01B from the GSK trial PRO-
HIV-002 (Leroux-Roels, et al., 2007) were studied. PBMCs were obtained 
a VH mutation rate of 0.3% (Weitkamp et al., 2003). In con-
trast, Wrammert et al. (2008) found the mutation rate in a 
secondary response to influenza vaccine vaccination to be 
6.5%. Thus, HIV-1–reactive antibodies in the initial response 
to HIV-1 Env in AHI have mutation frequencies that are 
more consistent with that of antibodies in a secondary anti-
body response than that of antibodies in an Env primary re-
sponse. These analyses raised the hypothesis that at the time 
of AHI, HIV-1 preferentially activated preexisting memory 
B cells that had been originally triggered by non–HIV-1 anti-
gens, but whose BCRs cross react with HIV-1 gp41, and 
upon contact with gp41 undergo antigen drive and clonal 
expansion. This hypothesis has been tested in three ways.
First, we isolated one clonal lineage (558) from AHI that 
was sufficiently large to infer an RUA and reverted interme-
diates, and demonstrated that the gp41 reactivity of this clonal 
lineage with the autologous Env was acquired after the RUA 
and one intermediate. Second, we asked if mutated Env-
reactive B cells could be isolated from the plasma cell rep-
ertoires  of  uninfected  subjects,  and  found  that,  indeed, 
uninfected subjects have gp41 Env-reactive B cells with B cell 
receptors that both bind Env and cross react with non-HIV-1 
antigens. Third, we asked if mutated IgM mAbs could be 
generated from HIV-1 infection that bind gp41 and gut flora, 
and we found one such IgM mAb 1E7 (Fig. S4). This reac-
tivity with gut flora could indicate that it is primarily gut 
flora–specific B cells that are triggered in AHI by HIV-1 Env 
gp41, or it could mean only that the initial responsive B cells 
to HIV-1 Env are polyreactive and gut flora antigens are simply 
one such common cross reaction.
It should be noted that although we used very sensitive 
methods (SPR) for studying the reactivity of unmutated an-
cestor antibodies with gp41 and autologous gp140 Env, a 
physiologically relevant interaction of gp41 with a membrane-
bound naive B cell receptor may have occurred in vivo, leading 
to B cell triggering. Our studies cannot rule out this possibility.
It is not known why many of the initial responding Env 
antibodies in AHI are polyreactive. We have previously shown 
that some of the rare broadly neutralizing mAbs are polyreac-
tive (Haynes et al., 2005), and for some of these antibodies, 
such as those that are directed to the gp41 membrane proxi-
mal neutralizing determinants, their polyreactivity appears to 
induce tolerance control of production of these types of anti-
bodies (Verkoczy et al., 2009). Mouquet et al. (2010) have 
demonstrated  that,  in  HIV-1  chronically  infected  subjects 
who have plasma broad neutralizing activity, 75% of all 
Env antibodies were polyreactive and that polyreactivity   
facilitates high-affinity binding to virions with few Env spikes. 
Thus, one possibility is that HIV-1 Env is processed in the 
spleen, lymph nodes, and MALT in such a manner as to pref-
erentially activate polyreactive B cells. If this is the case, then 
the antibodies that are induced in Env vaccination would have 
the same degree of polyreactivity as seen in HIV-1 infection. 
Studies are underway to address this issue.
The degree of polyclonality in the AHI response was strik-
ing, particularly in contrast to the highly clonal response seen in 2246 Early HIV-1 gp41-binding antibodies | Liao et al.
Antibodies from a given subject were regarded as clonally related if they 
met the following criteria for both the heavy and light chains: (a) They were 
inferred to use the same V and J gene segments. D-segment identification is 
subject to substantial uncertainty, so inferred differences in D-segment use 
were not sufficient to rule out clonal relatedness of two antibodies. (b) Iden-
tical CDR3 length. (c) 70% or greater nucleotide identity with CDR3. Phylo-
genetic  analysis  using  the  DNA  Maximum  Likelihood  method  of  the 
PHYLIP 3.63 package (Felsenstein, 2005) was conducted using the inferred 
unmutated common ancestor from SoDA as the root.
High-throughput  DNA  sequencing  of  Ig  V(D)J  gene  segments.  
Genomic DNA samples were isolated from aliquots of PBMCs of all five acute 
HIV-1 subjects using QIAamp DNA Mini kit (QIAGEN). Multiplexed 
primers targeting the V and J segments of the Ig heavy-chain were used to 
amplify the rearranged variable (V), diverse (D), and joining (J) segments of 
the Ig heavy chain. Six barcoded V(D)J libraries from independent aliquots 
of DNA template from each sample were amplified, pooled, and sequenced 
using the 454 platform with Titanium chemistry (Roche; Boyd et al., 2009). 
Each sample was sequenced to an mean depth of 3,300 total Ig VH sequences. 
Sequences with identical V, D, and J segment usage and identical V-D and 
D-J junctions were considered to be members of an individual B cell clone.
Design and synthesis of inferred unmutated common ancestor and 
phylogenetic intermediate antibodies. For each set of clonally related 
antibodies, Phylip’s DNA maximum likelihood (Felsenstein, 1973, 1981) 
and SoDA (Volpe et al., 2006) were used in conjunction to infer RUA and 
unobserved phylogenetic intermediates. These inferred RUA and interme-
diate VH and VL genes were synthesized (GenScript) and cloned as full-
length IgG1 for heavy chain and full-length  or  light chain genes into 
pcDNA3.1 plasmid (Invitrogen) using standard recombinant techniques.
Expression of VH and VL as full-length IgG1 recombinant mAb. The 
isolated Ig VH and VL gene pairs were assembled by PCR into the linear 
full-length Ig heavy- and light-chain gene expression cassettes for produc-
tion of recombinant mAbs by transfection in the human embryonic kidney 
cell line, 293T (American Type Culture Collection) using the methods as 
previously described (Liao et al., 2009). The purified PCR products of 
the paired Ig heavy- and light-chain gene expression cassettes were co- 
transfected into near confluent 293T cells grown in 6-well (2 µg of DNA for 
each cassette/well) tissue culture plates (Becton Dickson) using PolyFect 
(QIAGEN) or Effectene (QIAGEN), and the protocols recommended by 
the manufacturers. 6 to 8 h after transfection, the 293T cells were fed with 
fresh culture medium supplemented with 2% FCS and incubated at 37°C in 
a 5% CO2 incubator. Culture supernatants were harvested 3 d after transfec-
tion and quantified for expressed IgG levels and screened for antibody speci-
ficity.  The  average  concentration  of  recombinant  antibody  produced  in 
293T cells by transient transfection and used for screening specificity of anti-
body was 3.2 µg (+1.7 µg; n = 2,500). These screening assays of the trans-
fected supernatants were designed to identify higher affinity antibodies in 
supernatants of the transfected cell cultures when the recombinant antibodies 
were expressed at from 0.1 to 25 µg/ml in transient transfections. Antibodies 
identified as exhibiting binding activity to tested antigens in screening assays, 
as well as the inferred UCA and intermediate clonal antibodies, were pro-
duced on a larger scale so that screening assays could be replicated and broad-
ened to more fully define the range of binding activity of expressed plasma 
cell–derived antibodies. Purified recombinant antibodies were produced in 
bulk cultures by transient transfection using Ig heavy-and light-chain genes 
cloned in pcDNA plasmids (Liao et al., 2009). The linear Ig heavy- and 
light-chain gene expression cassettes used for production of recombinant   
antibodies for initial screening were cloned into pcDNA 3.3 (Invitrogen) for 
production of purified recombinant mAbs using standard molecular proto-
col, and then co-transfected into 293T cells cultured in T175 flasks using 
PolyFect (QIAGEN) or polyethylenimine (Smith et al., 2009) cultured in 
DME supplemented with 2% FCS. Recombinant mAbs were purified from 
culture supernatants of the transfected 293T cells using anti–human Ig heavy 
14 d after the second immunization (total of 42 d after the first dose, and   
14 d after fourth immunization (total of 182 d after the first dose) with the 
same immunogen (Leroux-Roels, et al., 2007). PBMCs were also obtained 
from two HIV-1 negative healthy donors and used for single plasma cell sorts 
for isolating VH and VL gens for generating recombinant antibodies. Addi-
tionally, PBMCs were obtained from another HIV-1–negative healthy donor 
and used for generation of EBV-transformed human cell cultures for pro-
duction human mAbs. All work related to human subjects was in compliance 
with Institutional Review Board protocols approved by the Duke Univer-
sity Health System Institutional Review Board, Rockefeller University 
Hospital Institutional Review Board; Institutional Review Board of the 
University of Alabama at Birmingham; University of North Carolina at 
Chapel Hill, Office of Human Research Ethic Biomedical Institutional Re-
view Board; and Ethics Comité, UZ Ghent, Ghent, Belgium.
Single-cell flow cytometry sorting strategy. PBMCs from blood or 
bone marrow samples were labeled with panels of fluorochrome antibody 
conjugates specific for human IgG-(PE), CD3 (PE-Cy5), CD16 (PE-Cy5), 
CD19 (APC-Cy7), CD20 (PE-Cy7), CD27 (Pacific Blue), CD235a (PE-
Cy5), IgD (PE), IgM (FITC; BD), and CD14 (PE-Cy5) and CD38 (APC-
Cy5.5; both from Invitrogen) as previously described (Wrammert et al., 
2008; Liao et al., 2009). All antibody reagents were titered and used at optimal 
concentrations for flow cytometry. As Wrammert et al. (2008) have shown 
that the antibody secreting cells (ASCs) present in human PBMC popula-
tions express a distinctive CD19+, CD38hi, IgD, CD20lo, or CD20 cell 
phenotype. To characterize single human ASCs, we sorted single plasma-
blasts/cytes  (CD3CD14CD16CD235aCD19+CD20CD27hiCD38hi) 
from human PBMC samples cells recovered from AHI and control subjects 
into the individual wells of 96-well plates containing 20 µl/well of RT reac-
tion buffer (Invitrogen) as previously described (Tomaras et al., 2008; Bar   
et al., 2009). Antigen-specific memory B cell sorts were performed for isola-
tion of HIV-1 gp120 Env-reactive antibodies from subjects immunized with 
gp120/NefTat/AS01B from the GSK trial PRO-HIV-002 (Leroux-Roels, 
et al., 2007) using AF647 and Pacific blue dual color labeled-B.W61D gp120 
using the method as previously described (Scheid et al., 2009).
PCR amplification of plasmablast/plasma cell immunoglobulin VH 
and VL genes. The Ig VH and VL genes of the sorted plasmablast were am-
plified by RT and nested PCR using the method as previously reported 
(Wardemann et al., 2003; Tiller et al., 2008; Wrammert et al., 2008; Liao   
et al., 2009). The PCR products amplified by this method contain enough 
coding region sequences for the constant regions of either heavy- or light-
chain genes for allowing the identification of IgH subclass and types of light 
chains (Liao et al., 2009). Isolated VH and VL genes were used for assembling 
full-length Ig IgG1 heavy- and light-chain expression cassette by overlap-
ping PCR to express recombinant IgG1 antibodies (Liao et al., 2009).
Sequencing, sequence annotation, quality control, and data man-
agement of Ig VH and VL sequences. All PCR products of Ig VH and VL 
genes were purified using a PCR purification kit (QIAGEN) and sequenced 
in forward and reverse directions using an ABI 3700 instrument and BigDye 
sequencing kit (Applied Biosystems). Base calling for each sample was per-
formed using Phred (Ewing and Green, 1998; Ewing et al., 1998). The for-
ward and reverse strands of the antibody genes were assembled into one final 
nucleotide sequence using a novel assembly algorithm based on the quality 
scores at each base position (Munshaw and Kepler, 2010). The estimated 
PCR artifact rate was 0.28 or 1 PCR artifact per 5 genes amplified. The 
isotype and subclasses of Ig heavy-chain and types of light-chain were deter-
mined by comparing the constant region sequences of the isolated Ig VH and 
VL PCR products with the constant region sequences of the known Ig iso-
types and subclass, , and  genes using a computer alignment algorithm 
(Smith and Waterman, 1981). The unmutated rearrangement of each qual-
ity-assured antibody sequence was determined using SoDA (Volpe et al., 
2006). Genetic information inferred by using SoDA, such as gene segment 
usage, somatic mutations, n-nucleotides, and CDR3 length is stored in a re-
lational database to facilitate subsequent statistical analysis.JEM Vol. 208, No. 11 
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binding to either control surfaces or control antibodies (HIV-1 gp120 for 
Env-immobilized surfaces and control mAb IS6 [antilipid] or Synagis [anti-
RSV] for mAb captured surfaces). Rate constants were measured using   
either the 1:1 Langmuir equation or bivalent analyte model (to account for 
the avidity of bivalent Ig molecules) and global curve fitting to binding 
curves obtained from mAb titrations. mAbs were injected at 30 µl/min for   
3 min, and Glycine-HCl pH 2.0 and surfactant P20 (0.01%) were used as the 
regeneration buffer.
Statistical analysis. All analysis datasets were compiled, and all analysis 
completed in SAS v9.2 (SAS, Inc.). For continuous measures (e.g., mutation 
rate) there were two types of tests performed. For two group comparisons 
between means, Student’s t tests with Satterthwaite variance estimates were 
performed in PROC TTEST. Where there were more than two groups 
where means were compared, the least squares means were tested using one 
degree of freedom F-tests in PROC GLM. For comparisons of count data, 
2 tests were used. When cell counts were low, Fisher’s exact tests were per-
formed in PROC FREQ.
Online supplemental material. Fig. S1 shows distribution of VH somatic 
mutation frequencies in AHI antibodies. Fig. S2 shows reactivity of antibody 
members of clonal lineages 558, 572, 712, 728, and 2495 with HIV-1 gp41, 
gut flora, and HEp-2 epithelial cells. Fig. S3 shows reactivity of antibody 
members of clone 558 with HIV-1 MN gp41 and gut flora in Western 
blots of blue native gels and SDS-PAGE under reducing and nonreducing 
conditions. Fig. S4 shows reactivity of IgM antibody 1E7 isolated from bone 
marrow of an AHI patient. Table S1 shows Ig isotypes of HIV-1–reactive 
antibodies and antibodies with unknown specificity isolated from AHI. 
Table S2 shows comparison of VH and VL usage of HIV-1–reactive antibod-
ies and antibodies with unknown specificity isolated from AHI. Table S3 
shows CDR3 length of Ig heavy (H),  (K), and  (L) chains of antigen-
reactive and nonreactive antibodies. Table S4 shows mutation frequencies 
of total framework and CDR regions in VH, VK, and VL gene segments of   
antigen-reactive and nonreactive antibodies. Table S5 shows gene family, 
mutation frequency, and CDR regions of anti–HIV-1 gp120 antibodies 
isolated from HIV-1 W61D gp120-immunized subjects. Table S6 shows   
HIV-1–positive clonal lineages identified from AHI patients. Tables S7–11 
show VH and VL sequences of clones 558, 572, 712, 728, and 2495, respec-
tively. Table S12 shows mutations in VH and VL CDR and framework regions 
of clone 558. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20110363/DC1.
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chain specific antibody-agarose beads (Sigma-Aldrich) using the previously 
described method (Liao et al., 2009). Purified antibodies used in the study 
were confirmed as having the typical patterns of predominant whole IgG in 
SDS-PAGE and Western blots under reducing and nonreducing conditions 
(Liao et al., 2009).
ELISA and Luminex assays for screening and characterization of 
antibody specificity. Concentration of recombinant mAbs secreted in the 
transfected 293T cell culture in the supernatants was determined using a 
previously described method (Fiebig et al., 2003). The expressed recombi-
nant mAb were assayed for antibody reactivity to HIV-1 antigens and to a 
panel of non–HIV-1 antigens by ELISA and Luminex assays (Liao et al., 2009; 
Tomaras et al., 2008). HIV-1 antigens included the Env peptides gp41   
immunodominant  region  peptide  (RVLAVERYLRDQQLLGIWGCS-
GKLICTTAVPWNASWSNKSLNK),  gp41  MPER  region  peptide 
(QQEKNEQELLELDKWASLWN),  HIV-1  MN  recombinant  gp41   
(Immunodiagnostics), HIV-1 group M consensus gp120 (Liao et al., 2006), 
HIV-1 group M consensus gp140 CFI (Liao et al., 2006), p66 (Worthington 
Biochemical), p55 (Protein Sciences), p31 (Genway), Nef (Genway), Tat (Ad-
vanced  BioScience), and  AT-2–inactivated HIV-1  ADA  virions  (Rossio   
et al., 1998; a gift from J. Lifson, National Cancer Institute, Frederick, MD). 
In addition, all antibodies derived from subjects 684–6 and 641–7 were as-
sayed against the corresponding autologous gp140 and gp120 Env proteins. 
The non–HIV-1 antigens tetanus toxoid (EMD) cardiolipin (Avanti Polar 
Lipids; Haynes et al., 2005) killed Cryptococcus neoformans (Perfect, 2006) and 
Candida  albicans  (Sherman,  1991;  Blankenship  et  al.,  2003)  and  lipid  A 
(Avanti Polar Lipids). In addition, reactivity of recombinant antibodies to 
whole-cell lysates of anaerobic and aerobic bacterial extracts (Kawatsu et al., 
2008) was tested. Bacterial whole-cell lysates were prepared using previously 
described methods (Kawatsu et al., 2008).
In brief, bacteria were inoculated from a stool specimen from 4 subjects 
and grown on agar plates under anaerobic or aerobic conditions at 30°C. 
Aerobic and anaerobic extracts were prepared separately, but the four indi-
vidual samples of each were combined. Bacteria grown in confluence were 
harvested by adding 5 ml PBS and gently scraping the agar surface with a cell 
scraper (Thermo Fisher Scientific). Surfaces were then rinsed with another   
5 ml PBS to remove any remaining bacteria and transferred to a 50-ml coni-
cal tube. The extract was treated with 100 µl of bacterial protease inhibitor 
cocktail (Sigma-Aldrich), and then sonicated with a Misonix 3000 Sonicator 
at maximum voltage for 15-s pulses, followed by 15-s rests on ice for 3 min. 
After sonication, 1.5 g of acid-washed glass beads (Sigma-Aldrich) was added 
to the extracts. The extracts were vortexed for 1 min at maximum setting, 
and then chilled for 1 min in an ice bath. This process was repeated four 
times for a total of five vortex-chill cycles. The resulting extracts were spun 
for 20 min at 3,000 g. The supernatants were harvested and measured for 
protein concentration by Nanodrop (Thermo Fisher Scientific). Samples 
were aliquoted and frozen at 80°C until they were used. In addition, all 
antibodies were also assayed for the reactivity to HEP-2 cells (Inverness 
Medical Professional Diagnostics) by indirect immunofluorescence staining 
(Haynes et al., 2005).
The apparent affinity of antibodies was calculated in molar concentra-
tion from EC50 values using a four parametric sigmoid curve fitting analysis. 
Antibodies were titrated at concentrations ranging from 50 to 0.2 µg/ml, and 
threefold dilutions were used in the Luminex assays. For antibodies with rel-
atively lower affinities, EC50 values were calculated by extrapolating the 
binding curve to the saturation level.
SPR analysis of antibody reactivity. SPR binding assays were performed 
on a BIAcore 3000 (BIAcore Inc.) maintained at 20°C. HIV-1 gp41 MN or 
oligomeric gp140 proteins (Con S gp140 and autologous Env gp140) were 
immobilized on a CM5 sensor chip by standard amine coupling, as previ-
ously described (Alam et al., 2008, 2009). In a separate CM5 sensor chip, 
human mAbs were captured on anti–human Fc antibody-coupled surfaces, 
and then human mAbs were captured to 200–500 response units. Specific 
binding responses of mAb binding were assessed by comparing nonspecific 2248 Early HIV-1 gp41-binding antibodies | Liao et al.
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